BCM
ADVM

BML Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

BML Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,057,526
Closed -$13.9M – 17
2025
Q3 		$13.9M Hold
3,057,526
– – 12.68% 3
2025
Q2 		$6.57M Buy
3,057,526
+315,209
+11% +$882K 4.97% 7
2025
Q1 		$12M Buy
2,742,317
+474,253
+21% +$2.14M 9.7% 4
2024
Q4 		$10.6M Hold
2,268,064
– – 6.58% 4
2024
Q3 		$15.9M Buy
2,268,064
+302,064
+15% +$2.19M 9.37% 6
2024
Q2 		$13.5M Buy
1,966,000
+1,132,883
+136% +$10.5M 9.62% 5
2024
Q1 		$11.8M Buy
833,117
+377,692
+83% +$5.74M 7.77% 4
2023
Q4 		$3.43M Buy
455,425
+63,925
+16% +$584K 2.6% 10
2023
Q3 		$5.87M Sell
391,500
-124,218
-24% -$2.23M 5.39% 6
2023
Q2 		$8.2M Sell
515,718
-191,000
-27% -$2.01M 7.38% 5
2023
Q1 		$5.07M Hold
706,718
– – 4.38% 7
2022
Q4 		$4.1M Buy
+706,718
New +$5.36M 3.91% 10

BML Capital Management's ADVM Position: Q4 2025 in Review

BML Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 3,057,526 shares — an estimated $13.9M sold.

BML Capital Management first reported a position in ADVM in Q4 2022 and held it in 12 quarters. The position peaked at $15.9M in Q3 2024. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.

  • BML Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • BML Capital Management sold 3,057,526 Adverum Biotechnologies shares in Q4 2025, an estimated $13.9M.
  • BML Capital Management first reported a position in Adverum Biotechnologies in Q4 2022 and held it in 12 quarters.
  • BML Capital Management's Adverum Biotechnologies position peaked at $15.9M in Q3 2024.
  • 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.

Based on BML Capital Management's 13F filing for Q4 2025, filed 3 Feb 2026.